PMID: 4909449Apr 18, 1970Paper

Bone marrow graft in man after conditioning by antilymphocytic serum

British Medical Journal
G MathéC Jasmin

Abstract

Allogeneic bone marrow grafts carried out after previous administration of antilymphocytic serum alone were attempted in 16 patients. Of these, six had acute myeloblastic leukaemia, four acute lymphoblastic leukaemia, and one a blast cell crisis in polycythaemia vera. Ten of these patients were in an overt phase of the disease and resistant to chemotherapy, while nine had complete agranulocytosis. In five of these patients erythrocyte and leucocyte antigenic markers demonstrated the establishment of the graft. One patient had thalassaemia major, and four others had aplasia of the bone marrow, in one case due to chloramphenicol poisoning and in another to virus hepatitis. The grafts were successful in the last two patients and transformed their clinical condition.No signs of early acute secondary disease were noted in any of the patients, either when the donor had been given antilymphocytic serum or when he was untreated. The grafts had no adoptive immunotherapeutic effect on the acute leukaemia. These observations have clearly shown that antilymphocytic serum has an immunosuppressive effect in man when it is used alone.

Associated Clinical Trials

Jul 21, 2003·Danielle Townsley, M.D., Danielle Townsley, M.D.

Citations

Jun 11, 2005·European Journal of Pediatrics·Lucien Corbeel
May 12, 2005·Lancet·Robert A Brodsky, Richard J Jones
Mar 18, 1982·The New England Journal of Medicine·B M CamittaE D Thomas
May 9, 1991·The New England Journal of Medicine·M A Moore, H Castro-Malaspina
May 8, 1997·The New England Journal of Medicine·N S Young, J Maciejewski
Aug 5, 2011·The New England Journal of Medicine·Phillip ScheinbergNeal S Young
Jan 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·N C ZoumbosN S Young
Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·B M Wimer
Jan 1, 1971·Transplantation Reviews·T E StarzlC G Halgrimson
Sep 7, 2001·The Journal of Clinical Investigation·W ZengN S Young
Jan 29, 2011·Haematologica·Nao YoshidaSeiji Kojima
Sep 19, 2003·Wiener klinische Wochenschrift·Klaus Geissler
Aug 12, 1971·The New England Journal of Medicine·E CotlierJ S O'Brien
Mar 30, 2007·Critical Reviews in Oncology/hematology·Martin SternCatherine Nissen-Druey
Oct 1, 1971·The American Journal of Medicine·H J MeuwissenR A Good
Nov 13, 2013·Seminars in Hematology·Phillip Scheinberg, Jichun Chen
Sep 15, 2000·Blood Reviews·S B Killick, J C Marsh
Jan 16, 2014·Autoimmunity Reviews·Osnat Jarchowsky Dolberg, Yair Levy
Aug 25, 2010·Blood·Regis Peffault de LatourNeal S Young
Feb 20, 2015·Hematology·Sophia R Balderman, Laura M Calvi
Aug 3, 2016·Transplant Immunology·Niels V RekersMichael Eikmans
Apr 25, 2000·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·C R de-MedeirosR Pasquini
Jul 28, 2004·Lancet·Judith C W Marsh, Edward C Gordon-Smith
Jan 1, 1972·Transplantation Reviews·D W van Bekkum

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.